← Eichor
Study identifier: NCT07607496 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

MacuTherm Performance Study in Patients With iAMD

Condition: Intermediate AMD  ·  Sponsor: OD-OS MacuTherm GmbH

PhaseNA
Planned participants240
Who can joinAll sexes, 60 Years to 90 Years
Healthy volunteersNo

About this study

The goal of this study is to demonstrate that photothermal therapy with the individually dosed treatment plan proposed by Macula Explorer delivered safely by Navilas® Laser System effectively improves the life of photoreceptors and reduces the progression of intermediate Age-related Macular Degeneration (iAMD) and preserves photoreceptors shown by Ellipsoid Zone Integrity (EZI). Participants will be randomized to either Treatment or Control Group. There will be 12 visits, monthly for the first 3 months, then quarterly until the end of the study after 2 years.

This description comes directly from the study's public registry record.

Talk to the study team

Jan Tode, Prof. Dr. med.  ·  +49 3328 31 282-100  ·  Jan.Tode@od-os.com

Always discuss trial participation with your own doctor first.

Locations (4)

Department of Ophthalmology at Hannover Medical SchoolHanover, GermanyNot Yet Recruiting
Department of Ophthalmology, University Medical Center Schleswig-HolsteinLübeck, GermanyNot Yet Recruiting
Potsdam Eye Clinic at GräfehausPotsdam, GermanyRecruiting
AugenNord Medical Practice and Surgical CenterSchleswig, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07607496